Label: PALGIC- carbinoxamine maleate tablet
PALGIC- carbinoxamine maleate solution

  • NDC Code(s): 0525-6748-01, 0525-6748-04, 0525-6748-05, 0525-6752-04, view more
    0525-6752-16, 0525-6752-30
  • Packager: Pamlab, L.L.C.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated 11/10

If you are a consumer or patient please visit this version.

  • DESCRIPTION

    Carbinoxamine maleate is a histamine-H1 receptor blocking agent.

    Each tablet contains 4 mg carbinoxamine maleate and the following inactive ingredients: anhydrous lactose, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate.

    Each 5 mL (teaspoonful) of oral solution contains 4 mg carbinoxamine maleate and the following inactive ingredients: artificial bubble gum flavor, citric acid (anhydrous), glycerin, methylparaben, propylene glycol, propylparaben, purified water, sodium citrate (hydrous) and sorbitol solution.

    Carbinoxamine maleate is freely soluble in water. Its structure is:

    carbinoxamine maleate chemical structure

    2-[(4-chlorophenyl)-2-pyridinylmethoxy]-N, N-dimethyl-ethanamine (Z)-2-butenedioate (1:1)

    C16H19CIN2O•C4H4O4

    MW = 406.86

    Close
  • CLINICAL PHARMACOLOGY

    Mechanism of Actions

    Carbinoxamine maleate, an ethanolamine derivative, is an antihistamine with anticholinergic (drying) and sedative properties. Carbinoxamine appears to compete with histamine (type H1) for receptor sites on effector cells in the gastrointestinal tract, blood vessels and respiratory tract.

    Pharmacokinetics and Metabolism

    Carbinoxamine is well absorbed from the GI tract and appears to be extensively metabolized by the liver, and excreted in the urine as inactive metabolites within 24 hours. Virtually no intact drug is extended in the urine.

    In a study comparing a controlled-release suspension and a solution of carbinoxamine, healthy volunteers were administered a single dose of 8 mg carbinoxamine. A time to maximum concentration (Tmax) was between 1.5 hours to 5 hours, a peak plasma concentration (Cmax) of about 24 ng/mL was observed, and extent of exposure (AUC) was about 286 ng hr/mL. The serum half-life is reported to be 10 to 20 hours.

    Drug/Food Interactions

    Carbinoxamine should not be used in patients with hypersensitivity to carbinoxamine. Carbinoxamine may increase the effects of other drugs such as barbiturates, TCAs, MAO inhibitors such as Phenelzine (Nardil), Tranylcypromine (Parnate), or Selegiline (Eldepryl), alcohol , other antihistamines, and CNS depressants. Carbinoxamine can be taken with or without food.

    Cardiovascular Effects

    Cardiac effects, including prolongation of QT interval have not been adequately studied. Unlike other newer antihistamines, severe adverse cardiovascular effects are uncommon, and usually limited to over dosage situations.

    Special Populations

    Pediatric Patients

    Carbinoxamine should not be used in newborn or premature infants. Neonates have an increased susceptibility to anticholinergic side effects, such as CNS excitation, which may lead to convulsions.

    Pregnancy and Lactation

    Safe use of carbinoxamine during pregnancy has not been established. Therefore, carbinoxamine should not be used in women who are, or may become pregnant. Carbinoxamine is in the FDA pregnancy Category C.

    Women who are breast-feeding should avoid use of carbinoxamine, since small amounts appear to be distributed into breast milk.

    Geriatric Patients

    Carbinoxamine is more likely to cause dizziness, sedation, and hypotension in elderly patients. The incidence of adverse reactions is higher in the elderly; therefore, a dosing adjustment may be necessary in this sub-population.

    Close
  • INDICATIONS AND USAGE

    Carbinoxamine maleate is effective for the symptomatic treatment of:

    Seasonal and perennial allergic rhinitis.

    Vasomotor rhinitis.

    Allergic conjunctivitis due to inhalant allergens and foods.

    Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.

    Dermatographism.

    As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.

    Amelioration of the severity of allergic reactions to blood or plasma.

    Close
  • CONTRAINDICATIONS

    Carbinoxamine maleate is contraindicated in children younger than 2 years of age.

    Carbinoxamine maleate is contraindicated in nursing mothers.

    Carbinoxamine maleate is contraindicated in patients who are hypersensitive to the drug or on monoamine oxidase inhibitor therapy. (See Drug Interactions section.)

    Close
  • WARNINGS

    Deaths have been reported in children less than 2 years of age who were taking antihistamines, including carbinoxamine-containing drug products, therefore, carbinoxamine maleate is contraindicated in children younger than 2 years of age (see CONTRAINDICATIONS).

    Antihistamines should be used with considerable caution in patients with: narrow angle glaucoma, stenosing peptic ulcer, symptomatic prostatic hypertrophy, bladder neck obstruction, pyloroduodenal obstruction.

    Close
  • PRECAUTIONS

    General

    As many other antihistamines, carbinoxamine maleate has an atropine-like action and, therefore, should be used with caution in patients with: increased intraocular pressure, hyperthyroidism, cardiovascular disease, hypertension.

    Antihistamines such as carbinoxamine maleate should not be used to treat lower respiratory tract symptoms, including asthma.

    Information for Patients

    Carbinoxamine maleate may cause drowsiness; alcohol, sedatives, and tranquilizers may increase the drowsiness effect. Avoid alcoholic beverages while taking this product. Do not take this product if you are taking sedatives or tranquilizers, without first consulting your doctor. Use caution when driving a motor vehicle or operating machinery.

    Drug Interactions

    Monoamine oxidase inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.

    Carbinoxamine maleate has additive effects with alcohol and other CNS depressants (hypnotics sedatives, tranquilizers, etc.).

    Carcinogenesis, Mutagenesis, Impairment of Fertility

    No long-term studies in animals have been performed to determine the possible effects of carbinoxamine maleate on carcinogenesis, mutagenesis, and fertility.

    Pregnancy 

    Pregnancy Category C

    Animal reproductive studies have not been conducted with carbinoxamine maleate. It is also not known whether carbinoxamine maleate can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Carbinoxamine maleate should be given to a pregnant woman only if clearly needed.

    Nursing Mothers

    Because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, use of carbinoxamine maleate is contraindicated in nursing mothers (see CONTRAINDICATIONS section).

    Pediatric Use

    Carbinoxamine maleate is contraindicated in children younger than 2 years of age (see CONTRAINDICATIONS).

    Neonates have an increased susceptibility to anticholinergic side effects, such as CNS excitation, which may lead to convulsions.

    Carbinoxamine maleate may diminish mental alertness in children. In the young child, particularly, they may produce excitation.

    Geriatric Use

    Carbixonaxime maleate is more likely to cause dizziness, sedation and hypotension in elderly patients (approximately 60 years or older). Sedating drugs may also cause confusion and over sedation in elderly. Therefore, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic renal, or cardiac function, and of concomitant disease or other drug therapy.

    Close
  • ADVERSE REACTIONS

    The most frequent adverse reactions are underlined:

    Body as a Whole: Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of mouth, nose and throat.

    Cardiovascular: Hypotension, headache, palpitations, tachycardia, extrasystoles.

    Hematologic: Hemolytic anemia, thrombocytopenia, agranulocytosis.

    Central Nervous System: Sedation, sleepiness, dizziness, disturbed coordination, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsions.

    Gastrointestinal:Epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation.

    Urogenital: Urinary frequency, difficult urination, urinary retention, early menses.

    Respiratory:Thickening of bronchial secretions, tightness of chest and wheezing, nasal stuffiness.

    Close
  • OVERDOSAGE

    Manifestations

    Antihistamine overdosage reactions may vary from central nervous system depression to stimulation. Stimulation is particularly likely in children. Atropine-like signs and symptoms - dry mouth; fixed, dilated pupils; flushing; and gastrointestinal symptoms may also occur.

    Especially in infants and children, antihistamine overdosage may cause hallucinations, convulsions, or death.

    The oral LD50 of carbinoxamine maleate in guinea pigs is 411 mg/kg.

    Treatment

    The treatment of overdosage with carbinoxamine maleate is essentially symptomatic and supportive. Vital signs (including respiration, pulse, blood pressure, and temperature) and EKG should be monitored. Induction of vomiting is not recommended. Activated charcoal should be given and gastric lavage should be considered after ingestion of a potentially life-threatening amount of drug. In the presence of severe anticholinergic effects, physostigmine may be useful. Vasopressors may be used to treat hypotension.

    Close
  • DOSAGE AND ADMINISTRATION

    Carbinoxamine maleate is contraindicated in children younger than 2 years of age (see CONTRAINDICATIONS).

    Carbinoxamine maleate should be taken on an empty stomach with water.

    DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.

    Carbinoxamine maleate dosage should be based on the severity of the condition and the response of the patient. The drug is well tolerated in doses as high as 24 mg daily, in divided doses, over prolonged periods. On the other hand, some patients respond to as little as 4 mg daily.

    Clinical experience suggests the following dosage schedules:

    Tablets

    Usual Adult Dosage:

    1 or 2 tablets (4 to 8 mg) 3 to 4 times daily

    Usual Child’s Dosage:

    Six to eleven years – 1/2 to 1 tablet (2 to 4 mg) 3 to 4 times daily

    Oral Solution

    Usual Adult Dosage:

    1 or 2 teaspoonfuls (4 to 8 mg) 3 to 4 times daily

    Usual Child's Dosage (approximately 0.2 to 0.4 mg/kg/day, divided into 3 to 4 doses)

    Six to eleven years - ½ to 1 teaspoonful (2 to 4 mg) 3 to 4 times daily

    Dosing for children 2 to 5 years of age should be based on weight whenever possible. The usual dosage for children 2 to 5 years of age is approximately 0.2 to 0.4 mg/kg/day, divided into 3 to 4 daily doses. In general, this corresponds to a dose of 1/4 to 1/2 teaspoonful (1 to 2 mg) 3 to 4 times daily.

    Close
  • HOW SUPPLIED

    Palgic (Carbinoxamine Maleate Tablets USP, 4 mg) is supplied as white, round, scored tablets, debossed “PAL” on one side and score “4” on the other side, and are supplied in bottles of 100 tablets, NDC 0525-6748-01 and bottles of 500 tablets, NDC 0525-6748-05.

    Palgic (Carbinoxamine Maleate Oral Solution, 4 mg/5 mL) is also supplied as clear, colorless liquid with a bubble gum aroma, and is supplied in 4 oz bottles NDC 0525-6752-04 and 16 oz bottles NDC 0525-6752-16.

    Store at controlled room temperature, 15°C to 30°C (59°F to 86°F) [See USP].

    Dispense in a tight, light-resistant container with a child-resistant closure as defined in the official compendium.

    Close
  • SPL UNCLASSIFIED SECTION

     Manufactured for:

    Pamlab, L.L.C.

    Covington, LA 70433

    Manufactured by:

    MIKART, INC.

    Atlanta, GA 30318

    Code 838B00

    Rev. 09/10

    Close
  • PRINCIPAL DISPLAY PANEL (TABLETS)
  • PRINCIPAL DISPLAY PANEL (ORAL SOLUTION)
  • INGREDIENTS AND APPEARANCE
    PALGIC 
    carbinoxamine maleate tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0525-6748
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    CARBINOXAMINE MALEATE (CARBINOXAMINE) CARBINOXAMINE MALEATE 4 mg
    Inactive Ingredients
    Ingredient Name Strength
    ANHYDROUS LACTOSE  
    MAGNESIUM STEARATE  
    CELLULOSE, MICROCRYSTALLINE  
    SODIUM STARCH GLYCOLATE TYPE A POTATO  
    Product Characteristics
    Color WHITE (WHITE) Score 2 pieces
    Shape ROUND (ROUND) Size 7mm
    Flavor Imprint Code PAL;4
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0525-6748-01 100 in 1 BOTTLE, PLASTIC
    2 NDC:0525-6748-05 500 in 1 BOTTLE, PLASTIC
    3 NDC:0525-6748-04 4 in 1 BOTTLE, PLASTIC
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA040442 08/21/2003
    PALGIC 
    carbinoxamine maleate solution
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0525-6752
    Route of Administration ORAL DEA Schedule     
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    CARBINOXAMINE MALEATE (CARBINOXAMINE) CARBINOXAMINE MALEATE 4 mg  in 5 mL
    Inactive Ingredients
    Ingredient Name Strength
    CITRIC ACID  
    GLYCERIN  
    METHYLPARABEN  
    PROPYLENE GLYCOL  
    PROPYLPARABEN  
    WATER  
    SODIUM CITRATE  
    SORBITOL  
    Product Characteristics
    Color      Score     
    Shape Size
    Flavor BUBBLE GUM Imprint Code
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0525-6752-04 118 mL in 1 BOTTLE, PLASTIC
    2 NDC:0525-6752-16 473 mL in 1 BOTTLE, PLASTIC
    3 NDC:0525-6752-30 30 mL in 1 BOTTLE, PLASTIC
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    ANDA ANDA040458 08/12/2003
    Labeler - Pamlab, L.L.C. (034426650)
    Close